Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Bionano Genomics (Nasdaq: BNGO) announced that its CEO Erik Holmlin, PhD, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Bionano Genomics (Nasdaq: BNGO) announced that its CEO Erik Holmlin, PhD, will present at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation is scheduled for September 8th, 2025, from 3:00 p.m. to 3:30 p.m. ET.
Investors can access the presentation through a webcast, and a replay will be available on Bionano's investor relations website at ir.bionano.com for a minimum of 30 days following the conference.
Details
News Market Reaction – BNGO
On Aug 25, the day this news came out, BNGO closed 2.50% above the previous close.
Data tracked by StockTitan Argus for the Aug 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8th, 2025.
Conference & Webcast Details
| Date: | September 8, 2025 |
| Time: | 3:00 p.m. to 3:30 p.m. ET |
| Presenter: | Erik Holmlin, PhD, CEO of Bionano |
| Webcast: | Link to Register |
A replay / recording of the session will be available following the conference through the Bionano website at ir.bionano.com for at least 30 days.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.
Contacts
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163
IR@bionano.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.